336 related articles for article (PubMed ID: 28315636)
1. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
Ong M; Ibrahim AM; Bourassa-Blanchette S; Canil C; Fairhead T; Knoll G
J Immunother Cancer; 2016; 4():64. PubMed ID: 27777773
[TBL] [Abstract][Full Text] [Related]
4. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.
Spain L; Higgins R; Gopalakrishnan K; Turajlic S; Gore M; Larkin J
Ann Oncol; 2016 Jun; 27(6):1135-1137. PubMed ID: 26951628
[TBL] [Abstract][Full Text] [Related]
5. The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma.
Hanna DL; Law SJ; Merrick SA; Heptinstall L; Bass P; Dupont P; Sheri A
Melanoma Res; 2020 Jun; 30(3):321-324. PubMed ID: 31764435
[TBL] [Abstract][Full Text] [Related]
6. Use of Ipilimumab and Pembrolizumab in Metastatic Melanoma in a Combined Heart and Kidney Transplant Recipient: A Case Report.
Soellradl I; Kehrer H; Cejka D
Transplant Proc; 2020 Mar; 52(2):657-659. PubMed ID: 32044081
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy.
Padala SA; Patel SK; Vakiti A; Patel N; Gani I; Kapoor R; Muhammad S
J Oncol Pharm Pract; 2021 Mar; 27(2):470-476. PubMed ID: 32580640
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients.
Zehou O; Leibler C; Arnault JP; Sayegh J; Montaudié H; Rémy P; Glotz D; Cordonnier C; Martin L; Lebbé C
Am J Transplant; 2018 Dec; 18(12):3065-3071. PubMed ID: 30107088
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
10. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
Maul LV; Weichenthal M; Kähler KC; Hauschild A
J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.
Alhamad T; Venkatachalam K; Linette GP; Brennan DC
Am J Transplant; 2016 Apr; 16(4):1332-3. PubMed ID: 26752406
[No Abstract] [Full Text] [Related]
14. Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature.
Jose A; Yiannoullou P; Bhutani S; Denley H; Morton M; Picton M; Summers A; van Dellen D; Augustine T
Transplant Proc; 2016 Nov; 48(9):3137-3141. PubMed ID: 27932166
[TBL] [Abstract][Full Text] [Related]
15. Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.
Deltombe C; Garandeau C; Renaudin K; Hourmant M
Transplantation; 2017 Sep; 101(9):e291. PubMed ID: 29633980
[No Abstract] [Full Text] [Related]
16. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
17. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
18. The transmission of donor-derived malignant melanoma to a renal allograft recipient.
Milton CA; Barbara J; Cooper J; Rao M; Russell C; Russ G
Clin Transplant; 2006; 20(5):547-50. PubMed ID: 16968479
[TBL] [Abstract][Full Text] [Related]
19. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.
Hurkmans DP; Verhoeven JGHP; de Leur K; Boer K; Joosse A; Baan CC; von der Thüsen JH; van Schaik RHN; Mathijssen RHJ; van der Veldt AAM; Hesselink DA
J Immunother Cancer; 2019 Jul; 7(1):182. PubMed ID: 31300068
[TBL] [Abstract][Full Text] [Related]
20. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
Hanna KS
Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]